I
INAB
vs
S&P 500
S&P 500
Over the past 12 months, INAB has underperformed S&P 500, delivering a return of -83% compared to the S&P 500's +14% growth.
Stocks Performance
INAB vs S&P 500
Performance Gap
INAB vs S&P 500
Performance By Year
INAB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IN8BIO, Inc.
Glance View
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 19 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The firm develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.
